Literature DB >> 7060035

Hemolytic-uremic syndrome associated with mitomycin therapy.

M D Pavy, E L Wiley, M D Abeloff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7060035

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  7 in total

1.  The haemotoxicity of mitomycin in a repeat dose study in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Edward C Gordon-Smith; Andrew M Pilling; Kai Chiu Liu; Sian Rizzo; Susan Sulsh; John A Turton
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Reversible microangiopathic hemolytic anemia after mitomycin C.

Authors:  D J Perry
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 4.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

5.  Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat.

Authors:  V Cattell
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

6.  Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity.

Authors:  T J Perren; G Blackledge; J J Mould; A D Chetiyawardana; M Morrison; A Hancock
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

7.  Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.

Authors:  J van der Meer; E G de Vries; R Vriesendorp; P H Willemse; A J Donker; J G Aalders
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.